Heparin cofactor II is an independent protective factor against peripheral arterial disease in elderly subjects with cardiovascular risk factors

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 2, 2009, Pages 127-134

  Aihara, Ken Ichi ^a   Azuma, Hiroyuki ^a   Akaike, Masashi ^a   Kurobe, Hirotsugu ^a   Takamori, Nobuyuki ^b   Ikeda, Yasumasa ^a   Sumitomo, Yuka ^a   Yoshida, Sumiko ^a   Yagi, Shusuke ^a   Iwase, Takashi ^a   Ishikawa, Kazue ^a   Sata, Masataka ^a   Kitagawa, Tetsuya ^a   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Health Insurance Naruto Hospital   (Japan)

Author keywords

Heparin cofactor II; Peripheral arterial disease; Thrombin

Indexed keywords

HEPARIN COFACTOR II;

AGE; AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROTECTION; PROTEIN FUNCTION; SMOKING;

EID: 67549127938     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E695     Document Type: Article

References (46)

1. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D: Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med, 1992; 326:381-386
2. McKenna M, Wolfson S, Kuller L: The ratio of ankle and arm arterial pressureas an independent predictor of mortality. Atherosclerosis, 1991; 87:119-128
3. Smith GD, Shipley MJ, Rose G: Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation, 1990; 82:1925-1931
4. Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, Wilson PW: Theankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med, 2003; 163:1939-1942
5. Ouriel K: Peripheral arterial disease. Lancet, 2001; 358:1257-1264
6. Stoffers HE, Rinkens PE, Kester AD, Kaiser V, Knottnerus JA: The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease. Int J Epidemiol, 1996; 25:282-290
7. McDermott MM, Mehta S, Greenland P: Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med, 1999; 159:387-392
8. Criqui MH, Fronek A, Klauber MR, Barrett-Connor E, Gabriel S: The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population. Circulation, 1985; 71:516-522
9. McDermott MM, Greenland P, Liu K, Guralnik JM, Celic L, Criqui MH, Chan C, Martin GJ, Schneider J, Pearce WH, Taylor LM, Clark E: The ankle brachialindex is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med, 2002; 136:873-883
10. Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, Sackett DL, Strandness DE Jr, Taylor LM: Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation, 1996; 94:3026-3049
11. Ouriel K: Detection of peripheral arterial disease in primary care. JAMA, 2001; 286:1380-1381
12. Brevetti G, Silvestro A, Schiano V, Chiariello M: Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value off low-mediated dilation to ankle-brachial pressure index. Circulation, 2003; 108:2093-2098
13. McDermott MM, Greenland P, Green D, Guralnik JM, Criqui MH, Liu K, Chan C, Pearce WH, Taylor L, Ridker PM, Schneider JR, Martin G, Rifai N, Quann M, Fornage M: D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation, 2003; 107:3191-3198
14. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemicatherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterialdisease. JAMA, 2001; 285:2481-2485
15. Tseng CH: Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan. Diabetes Care, 2004; 27:517-521
16. Langlois M, Duprez D, Delanghe J, De Buyzere M, Clement DL: Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation, 2001; 103:1863-1868
17. Pradhan AD, Rifai N, Ridker PM: Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation, 2002; 106:820-825
18. O'Hare AM, Glidden DV, Fox CS, Hsu CY: High prevalence of peripheralarterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation, 2004; 109:320-323
19. Hering J, Amann B, Angelkort B, Rottmann M: Thrombin-antithrombin complex and the prothrombin fragment in arterial and venous blood of patients with peripheral arterial disease. Vasa, 2003; 32:193-197
20. Reininger CB, Graf J, Reininger AJ, Spannagl M, Steckmeier B, Schweiberer L: Increased platelet and coagulatory activity indicate ongoing thrombogenesis in peripheral arterial disease. Thromb Res, 1996; 82:523-532
21. Tollefsen DM, Pestka CA, Monafo WJ: Activation of heparin cofactor by dermatan sulfate. J Biol Chem, 1983; 258:6713-6716
22. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM: Heparin cofactor inhibits arterial thrombosis after endothelial injury. J Clin Invest, 2002; 109:213-219
23. Vicente CP, He L, Pavao MS, Tollefsen DM: Antithrombotic activity of dermatan sulfate in heparin cofactor -deficient mice. Blood, 2004; 104:3965-3970
24. Wight TN, Lara S, Riessen R, Le Baron R, Isner J: Selective deposits of versicanin the extracellular matrix of restenotic lesions from human peripheral arteries. Am J Pathol, 1997; 151:963-973
25. Kanagawa Y, Shigekiyo T, Aihara K, Akaike M, Azuma H, Matsumoto T: Molecular mechanism of type congenital heparin cofactor (HC) deficiency caused by a missense mutation at reactive P2 site: HC Tokushima. Thromb Haemost, 2001; 85:101-107
26. Takamori N, Azuma H, Kato M, Hashizume S, Aihara K, Akaike M, Tamura K, Matsumoto T: High plasma heparin cofactor activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation, 2004; 109:481-486
27. Aihara K, Azuma H, Takamori N, Kanagawa Y, Akaike M, Fujimura M, Yoshida T, Hashizume S, Kato M, Yamaguchi H, Kato S, Ikeda Y, Arase T, Kondo A, Matsumoto T: Heparin cofactor is a novel protective factor against carotidatherosclerosis in elderly individuals. Circulation, 2004; 109:2761-2765
28. Tollefsen DM: Does heparin cofactor modulate atherosclerosis and restenosis ? Circulation, 2004; 109:2682-2684
29. Aihara K, Azuma H, Akaike M, Ikeda Y, Sata M, Takamori N, Yagi S, Iwase T, Sumitomo Y, Kawano H, Yamada T, Fukuda T, Matsumoto T, Sekine K, Sato T, Nakamichi Y, Yamamoto Y, Yoshimura K, Watanabe T, Nakamura T, Oomizu A, Tsukada M, Hayashi H, Sudo T, Kato S, Matsumoto T: Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofac-torII-deficient mice. J Clin Invest, 2007; 117:1514-1526
30. Vicente CP, He L, Tollefsen DM: Accelerated atherogenesis and neointimaformation in heparin cofactor deficient mice. Blood, 2007; 110:4261-4267
31. Narayanan S: Multifunctional roles of thrombin. Ann Clin Lab Sci, 1999; 29:275-280
32. Bar-Shavit R, Benezra M, Eldor A, Hy-Am E, Fenton JW, 2nd, Wilner GD, Vlodavsky I: Thrombin immobilized to extracellular matrix is a potent mitogen for vascular smooth muscle cells: nonenzymatic mode of action. Cell Regul, 1990; 1:453-463
33. Chen LB, Buchanan JM: Mitogenic activity of blood components. Thrombin and prothrombin. Proc Natl Acad Sci USA, 1975; 72:131-135
34. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW, 2nd, Coughlin SR, Owens GK: Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest, 1993; 91:94-98
35. Derian CK, Damiano BP, D'Andrea MR, Andrade-Gordon P: Thrombin regulation of cell function through protease-activated receptors: implications for therapeutic intervention. Biochemistry (Mosc), 2002; 67:56-64
36. Hirano K, Kanaide H: Role of protease-activated receptors in the vascular system. J Atheroscler Thromb, 2003; 10:211-225
37. Yanada M, Kojima T, Ishiguro K, Nakayama Y, Yamamoto K, Matsushita T, Kadomatsu K, Nishimura M, Muramatsu T, Saito H: Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood, 2002; 99:2455-2458
38. Aihara K, Azuma H, Akaike M, Ikeda Y, Yamashita M, Sudo T, Hayashi H, Yamada Y, Endoh F, Fujimura M, Yoshida T, Yamaguchi H, Hashizume S, Kato M, Yoshimura K, Yamamoto Y, Kato S, Matsumoto T: Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem, 2004; 279:35798-35802
39. de Agostini AI, Watkins SC, Slayter HS, Youssoufian H, Rosenberg RD: Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol, 1990; 111:1293-1304
40. Tollefsen DM: Insight into the mechanism of action of heparin cofactor. Thromb Haemost, 1995; 74:1209-1214
41. Tollefsen DM: Heparin cofactor deficiency. Arch Pathol Lab Med, 2002; 126:1394-1400
42. Rosenberg LC, Choi HU, Tang LH, Johnson TL, Pal S, Webber C, Reiner A, Poole AR: Isolation of dermatan sulfate proteoglycans from mature bovine articularcartilages. J Biol Chem, 1985; 260:6304-6313
43. Choi HU, Johnson TL, Pal S, Tang LH, Rosenberg L, Neame PJ: Characterization of the dermatan sulfate proteoglycans, DS-PGI and DS-PG, from bovine articular cartilage and skin isolated by octyl-sepharose chromatography. J Biol Chem, 1989; 264:2876-2884
44. Corral J, Aznar J, Gonzalez-Conejero R, Villa P, Minano A, Vaya A, Carrell RW, Huntington JA, Vicente V: Homozygous deficiency of heparin cofactor: relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis. Circulation, 2004; 110:1303-1307
45. Schillinger M, Exner M, Sabeti S, Mlekusch W, Amighi J, Handler S, Quehenberger P, Kalifeh N, Wagner O, Minar E: High plasma heparin cofactor activity protects from restenosis after femoropopliteal stenting. Thromb Haemost, 2004; 92:1108-1113
46. Giri TK, Ahn CW, Wu KK, Tollefsen DM: Heparin cofactor levels do not predict the development of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol, 2005; 25:2689-2690